Evidence map›Paper›PMID 27871278›Full record

ArticleBMC cancer2016

The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer.

Qin Li, Lei Zhang, XiuHong Li, Han Yan, Liuting Yang, Yingying Li, Teng Li, Jing Wang, Bangwei Cao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Qin LiDepartment of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Lei ZhangDepartment of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
XiuHong LiResearch Experiments Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Han YanDepartment of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Liuting YangDepartment of Biochemistry and Molecular Biology, Basic Medical College, Shanxi Medical University, Taiyuan, China.
Yingying LiDepartment of Pathology and Pathophysiology, Basic Medical College, Capital Medical University, Beijing, China.
Teng LiDepartment of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Jing WangDepartment of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Bangwei CaoDepartment of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China. oncology@ccmu.edu.cn.
Beijing Friendship Hospital · CNCapital Medical University · CNShanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrognostic factors aid in the stratification and treatment of cancer. This study evaluated the prognostic significance of human epidermal growth factor receptor (HER) family members (HER1-4) expression in patients with operable pancreatic cancer.

methodsThe expression of individual HER proteins in patient tissue specimens was detected by immunohistochemistry staining. Patient follow-up time was between 1.0 and 78.1 months.

resultsPositive expression of HER1, HER2, HER3 and HER4 was detected in 41.4, 60.0, 24.3 and 65.7% of cases, respectively. Kaplan-Meier analysis revealed that HER3 positive expression was associated with decreased median survival time (12.0 vs. 25.6 months for HER3 positive and negative groups, respectively; P = 0.013). Cox's regression confirmed that positive HER3 expression was an independent predictor of poor survival (RR = 3.684, P = 0.001). In contrast, HER4 negative patients had a significantly decreased median survival time when compared with HER4 positive patients (11.4 vs. 25.6 months, respectively; P = 0.027). However, HER4 was not an independent predictor of survival. No significant association between HER1 or HER2 expression and survival was observed (P = 0.626 & P = 0.859, respectively).

conclusionsHER3 is an independent prognostic marker for patients with operable pancreatic cancer. HER4 may also be of potential prognostic value in this disease and deserves further attention.

Indexed as

AdultAgedBiomarkers, TumorCell Line, TumorErb-b2 Receptor Tyrosine KinasesErbB ReceptorsFemaleGene ExpressionHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedMultigene FamilyNeoplasm StagingPancreatic NeoplasmsBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesErbB ReceptorsReceptor, ErbB-3Receptor, ErbB-4HER1HER2HER3Pancreatic cancerPrognosis

Identifiers

PMID27871278
PMCPMC5117489
OpenAlexW2555428738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.